Nonclinical Factors Drive Antibiotic Choice in Pediatric CAP

Share this content:
Nonclinical Factors Drive Antibiotic Choice in Pediatric CAP
Nonclinical Factors Drive Antibiotic Choice in Pediatric CAP

THURSDAY, March 9, 2017 (HealthDay News) -- For children with community-acquired pneumonia (CAP), patient and nonclinical characteristics are associated with receipt of macrolides and broad-spectrum antibiotics versus amoxicillin, according to a study published online March 7 in Pediatrics.

Lori K. Handy, M.D., from the Alfred I. DuPont Hospital for Children in Wilmington, Del., and colleagues conducted a retrospective cohort study in an outpatient pediatric primary care network to examine the patient and clinician characteristics associated with prescription of amoxicillin versus macrolide or broad-spectrum antibiotics for CAP.

The researchers found that 40.7, 42.5, and 16.8 percent of the 10,414 children received amoxicillin, macrolides, and broad-spectrum antibiotics, respectively. Patient age ≥5 years, previous antibiotic receipt, and private insurance were factors associated with increased odds of receipt of macrolides versus amoxicillin (adjusted odds ratios, 6.18, 1.79, and 1.47, respectively). Across clinics, the predicted probability of a child being prescribed a macrolide varied from 0.22 to 0.83. Suburban practice and private insurance were nonclinical characteristics associated with increased odds of receipt of broad-spectrum antibiotics versus amoxicillin (adjusted odds ratios, 7.50 and 1.42, respectively).

"Factors unlikely related to the microbiologic etiology of CAP were significant drivers of antibiotic choice," the authors write. "Understanding drivers of off-guideline prescribing can inform targeted antimicrobial stewardship initiatives."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »